Clearstone Central Laboratories
announced that it has entered into a partnership with
Mitsubishi Chemical Medience Corporation
(Mitsubishi). This preferred provider relationship provides clients of both companies with access to CAP-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and around the world. The cross-collaboration opens access for Mitsubishi clients not only to Clearstone’s lab in China but to its global laboratory network, and creates a new solution for Clearstone clients to access Mitsubishi’s lab network in Japan.
“We are very pleased to announce the Mitsubishi partnership given the value and opportunities it creates for our clients”, said Clearstone CEO Lewis Cameron. “Mitsubishi is well established in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China. We look forward to aligning our operational and business development activities, as well as providing our clients with access to the Japanese market”.
This announcement follows a collaborative agreement that Clearstone signed with the Esoterix Clinical Trials Services division of LabCorp last year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.